Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Kala Pharmaceuticals Inc
KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. Address: 1167 Massachusetts Avenue, Arlington, MA, United States, 02476
Analytics
Objectif de Cours de WallStreet
15 USDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés KALA
Analyse des dividendes KALA
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes KALA
Valorisation des titres KALA
financières KALA
Résultats | 2019 | Dynamique |